These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30989487)

  • 1. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
    Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
    Schmid A; Friess D; Mansouri Taleghani B; Keller P; Mueller BU; Baerlocher GM; Leibundgut K; Pabst T
    Leuk Lymphoma; 2015 Mar; 56(3):608-14. PubMed ID: 24884311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
    Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
    Flomenberg N; Comenzo RL; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
    Kumar SK; Mikhael J; Laplant B; Lacy MQ; Buadi FK; Dingli D; Gertz MA; Laumann K; Miceli T; Mahlman M; Bergsagel LP; Hayman SR; Reeder C; Stewart AK; Dispenzieri A; Gastineau DA; Winters JL
    Bone Marrow Transplant; 2014 Feb; 49(2):201-5. PubMed ID: 24185588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
    Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
    Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
    DiPersio JF; Stadtmauer EA; Nademanee A; Micallef IN; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Früehauf S; Horwitz M; Cooper D; Bridger G; Calandra G;
    Blood; 2009 Jun; 113(23):5720-6. PubMed ID: 19363221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor (Mozobil).
    Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
    [No Abstract]   [Full Text] [Related]  

  • 16. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
    Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
    Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
    He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
    Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
    Bakeer M; Zubair AC; Roy V
    Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
    Gregory KM; Rao KV; Armistead PM
    Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.